RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable
If daraxonrasib shrinks metastatic tumours this well, use it before surgery to make more locally advanced tumours operable.
Surgery remains the only cure. Only ~20% present resectable; another ~30% are borderline or locally advanced. Response rates with daraxonrasib and zoldonrasib combinations exceed those of FOLFIRINOX, and ctDNA clearance is frequent.
Pages like this
not linked directly; found by shared links- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares Daraxonrasib, KRAS & RAS inhibitors, KRAS, The undruggable drivers.
- PairingG12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)
Shares Zoldonrasib, Daraxonrasib, KRAS, Pancreatic ductal adenocarcinoma.
- CompanyRevolution Medicines
Shares Zoldonrasib, Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers.
- CompanyQuanta Therapeutics
Shares Daraxonrasib, KRAS & RAS inhibitors, KRAS, The undruggable drivers.
- ProductMRTX1133
Shares KRAS & RAS inhibitors, KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- IdeaCovalent chemistry for the RAS mutations that still have no drug
Shares Daraxonrasib, KRAS & RAS inhibitors, KRAS, The undruggable drivers.
- ProductElironrasib
Shares KRAS & RAS inhibitors, KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- Key paperOstrem and Shokat: the hidden pocket that made KRAS G12C druggable
Shares Daraxonrasib, KRAS & RAS inhibitors, KRAS, The undruggable drivers.